The FDA approved alogliptin (Nesina), a dipeptidyl peptidase-4 inhibitor, for the treatment of type 2 diabetes. Additionally, two combination drugs that include alogliptin were approved: alogliptin combined with metformin (Kazano) and alogliptin combined with pioglitazone (Oseni).

Keywords: Diabetes Mellitus, Type 2, Dipeptidyl-Peptidases and Tripeptidyl-Peptidases, Hypoglycemic Agents, Metformin, Piperidines, Thiazolidinediones, Uracil

< Back to Listings